Skip to main content

Table 1 Study Characteristics and Pregnancy Rates

From: A retrospective analysis of incident pregnancy in phase 1 and 2a HIV-1 vaccine study participants does not support concern for adverse pregnancy or birth outcomes

Study Study Treatment Participating Countries 1 N females of reproductive potential N participants reporting one or more pregnancies Pregnancies (main study) Pregnancies (Long-term followup) Pregnancies (total) rate main rate ltfu rate total Study Reference
HIVNET 026 canarypox + protein BR, HT, PE, TT 60 6 7 0 7 8.05 n/a 8.05 http://www.ncbi.nlm.nih.gov/pubmed/17693888
HVTN 039 canarypox US 30 0 0 0 0 0.00 n/a 0.00 http://www.ncbi.nlm.nih.gov/pubmed/16136469
HVTN 040 VEE ZA, BW, US 17 2 2 0 2 13.33 n/a 13.33 http://www.ncbi.nlm.nih.gov/pubmed/22914365
HVTN 041 protein US 22 0 0 0 0 0.00 n/a 0.00 http://www.ncbi.nlm.nih.gov/pubmed/17049679
HVTN 042 canarypox + lipopeptide US 73 7 8 0 8 4.49 n/a 4.49 http://www.ncbi.nlm.nih.gov/pubmed/25253665
HVTN 044 DNA US 23 1 1 0 1 2.70 n/a 2.70 http://www.ncbi.nlm.nih.gov/pubmed/21940420
HVTN 045 DNA US 20 2 2 0 2 10.00 n/a 10.00 http://www.ncbi.nlm.nih.gov/pubmed/16831092
HVTN 048 DNA BW, US 15 3 3 0 3 14.29 n/a 14.29 http://www.ncbi.nlm.nih.gov/pubmed/18055072
HVTN 049 DNA + protein US 45 2 2 0 2 3.77 n/a 3.77 http://www.ncbi.nlm.nih.gov/pubmed/21451004
HVTN 050 Ad5 BR, DR, HT, MW, PE, PR, ZA, TH, US 162 20 5 21 26 3.14 3.48 3.41 http://www.ncbi.nlm.nih.gov/pubmed/20854108
HVTN 052 DNA US 76 1 1 0 1 1.61 n/a 1.61 NCT00071851
HVTN 054 Ad5 US 21 0 0 0 0 0.00 n/a 0.00 http://www.ncbi.nlm.nih.gov/pubmed/21048953
HVTN 055 FPV + MVA BR, US 74 2 2 0 2 2.60 n/a 2.60 http://www.ncbi.nlm.nih.gov/pubmed/21216311
HVTN 056 peptide US 35 1 1 0 1 2.27 n/a 2.27 http://www.ncbi.nlm.nih.gov/pubmed/18996425
HVTN 057 DNA + Ad5 boost US 30 0 0 0 0 0.00 n/a 0.00 NCT00091416
HVTN 059 VEE BW, ZA, US 37 3 3 0 3 8.57 n/a 8.57 http://www.ncbi.nlm.nih.gov/pubmed/22914365
HVTN 060 DNA + IL12 DNA + peptide TH, US 69 3 3 0 3 4.11 n/a 4.11 http://www.ncbi.nlm.nih.gov/pubmed/22242162
HVTN 063 DNA + IL12 DNA + IL15 DNA BR, US 53 0 0 0 0 0.00 n/a 0.00 http://www.ncbi.nlm.nih.gov/pubmed/22242162
HVTN 064 peptide US 28 1 1 0 1 3.70 n/a 3.70 http://www.ncbi.nlm.nih.gov/pubmed/19786145
HVTN 065 DNA + MVA US 69 2 2 0 2 2.86 n/a 2.86 http://www.ncbi.nlm.nih.gov/pubmed/21282192
HVTN 067 DNA + MVA US 15 0 0 0 0 0.00 n/a 0.00 http://www.ncbi.nlm.nih.gov/pubmed/22398243
HVTN 068 DNA + Ad5 US 30 0 0 0 0 0.00 n/a 0.00 http://www.ncbi.nlm.nih.gov/pubmed/26908875
HVTN 069 DNA + Ad5 PE, US 37 5 1 5 6 2.70 6.17 5.08 http://www.ncbi.nlm.nih.gov/pubmed/21931737
HVTN 070 DNA + IL12 DNA US 59 4 4 0 4 7.27 n/a 7.27 http://www.ncbi.nlm.nih.gov/pubmed/23840043
HVTN 071 Ad5 US 21 1 1 0 1 4.76 0.00 1.09 http://www.ncbi.nlm.nih.gov/pubmed/23151505
HVTN 072 DNA + Ad5 + Ad35 US 4 0 0 0 0 0.00 0.00 0.00 NCT00472719
HVTN 073/E DNA + MVA + protein ZA, US 22 2 3 0 3 5.45 0.00 5.00 http://www.ncbi.nlm.nih.gov/pubmed/27098021
HVTN 076 DNA + Ad5 US 6 0 0 0 0 0.00 0.00 0.00 NCT00955006
HVTN 077 DNA + Ad5 + Ad35 US 81 5 1 6 7 1.30 2.10 1.93 http://www.ncbi.nlm.nih.gov/pubmed/26587311
HVTN 078 attenuated vaccinia + Ad5 CH 57 1 1 0 1 1.45 n/a 1.45 http://www.ncbi.nlm.nih.gov/pubmed/25271627
HVTN 080 DNA + IL12 DNA US 27 0 0 0 0 0.00 n/a 0.00 http://www.ncbi.nlm.nih.gov/pubmed/23840043
HVTN 082 DNA + Ad5 US 8 0 0 0 0 0.00 0.00 0.00 NCT01054872
HVTN 083 Ad5 US 78 4 1 4 5 1.75 1.20 1.28 http://www.ncbi.nlm.nih.gov/pubmed/26475930
HVTN 084 Ad5 BR, PE, CH, US 82 16 0 19 19 0.00 5.18 4.70 http://www.ncbi.nlm.nih.gov/pubmed/31748227
HVTN 085 Ad5 US 37 4 0 4 4 0.00 2.35 2.11 NCT01479296
HVTN 086 DNA + MVA + protein ZA 95 9 2 7 9 2.17 3.32 2.97 http://www.ncbi.nlm.nih.gov/pubmed/27583368
HVTN 087 DNA + IL12 DNA + VSV US 35 1 0 1 1 0.00 3.85 1.49 https://www.ncbi.nlm.nih.gov/pubmed/30235286
HVTN 088 protein US 13 2 2 0 2 7.41 n/a 7.41 https://www.ncbi.nlm.nih.gov/pubmed/30615119
HVTN 090 VSV US 29 5 0 6 6 0.00 7.89 6.45 http://www.ncbi.nlm.nih.gov/pubmed/26199949
HVTN 092 DNA + attenuated vaccinia CH, US 76 2 2 0 2 3.64 0.00 3.03 NCT01783977
HVTN 094 DNA + MVA US 30 3 1 2 3 2.27 6.45 4.00 https://www.ncbi.nlm.nih.gov/pubmed/28727817
HVTN 096 DNA + attenuated vaccinia + protein CH 49 10 3 9 12 4.35 3.95 4.04 https://www.ncbi.nlm.nih.gov/pubmed/31601541
HVTN 097 canarypox + protein ZA 49 2 2 0 2 3.85 n/a 3.85 https://www.ncbi.nlm.nih.gov/pubmed/31534016
HVTN 098 DNA + IL12 DNA US 40 1 1 0 1 1.75 n/a 1.75 NCT02431767
HVTN 100 canarypox + protein ZA 109 4 4 0 4 1.82 n/a 1.82 https://www.ncbi.nlm.nih.gov/pubmed/29898870
HVTN 105 DNA + protein US 48 0 0 0 0 0.00 n/a 0.00 https://www.ncbi.nlm.nih.gov/pubmed/31566579
HVTN 106 DNA + MVA CH, US 44 2 2 0 2 4.08 n/a 4.08 NCT02296541
HVTN 110 Ad4 + protein US 4 0 0 0 0 0.00 n/a 0.00 NCT02771730
HVTN 111 DNA + protein ZA, TZ, ZM 65 1 1 0 1 1.59 n/a 1.59 https://www.ncbi.nlm.nih.gov/pubmed/31900486
HVTN 112 DNA + VSV US 5 0 0 0 0 0.00 n/a 0.00 NCT02654080
HVTN 203 canarypox + protein US 81 4 5 0 5 4.24 n/a 4.24 http://www.ncbi.nlm.nih.gov/pubmed/17106277
HVTN 204 DNA + Ad5 BR, HT, JM, ZA, US 254 18 18 0 18 3.01 n/a 3.01 http://www.ncbi.nlm.nih.gov/pubmed/21857901
HVTN 205 DNA + MVA PE, US 124 10 5 6 11 4.17 2.80 3.29 http://www.ncbi.nlm.nih.gov/pubmed/24403557
Total    2673 172 103 90 193 3.09 3.22 3.15  
  1. 1 – ISO 3166 codes for countries and territories: BR Brazil, BW Botswana, CH Switzerland, DO Dominican Republic, HT Haïti, JM Jamaica, PE Peru, PR Puerto Rico, MW Malawi, TH Thailand, TT Trinidad and Tobago, TZ Tanzania, US United States, ZA South Africa, ZM Zambia